Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Otitis Externa”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed1994

Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogs.

Combinations of EDTA-Tris and two aminoglycoside antibiotics (amikacin and neomycin) were tested for synergistic activities against the microorganisms associated with otitis externa in dogs and for the solutions' stability over time. Synergistic activity was observed when EDTA-Tris plus amikacin and EDTA-Tris plus neomycin were tested against Staphylococcus intermedius, Proteus mirabilis, Pseudomonas aeruginosa, and Escherichia coli, but not against Candida albicans. Stability studies over a 3-month period indicated that the test solutions were stable at room temperature and that their antimicrobial activity was maintained.

Amikacin↗
PubMed2002

Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.

Minimum inhibitory concentrations for enrofloxacin were determined for 63 bacterial isolates from dogs with otitis externa or urinary tract infections. Development of resistant mutants was determined after exposing the isolates to enrofloxacin in vitro for up to five serial passages. Results indicated that Pseudomonas aeruginosa and Enterococcus spp isolates exposed to enrofloxacin developed resistance rapidly, whereas Klebsiella, Proteus, and Streptococcus spp were less likely to develop resistance. Despite the presence of enrofloxacin pressure, no resistant bacteria developed in the Escherichia coli and staphylococcal isolates. In many isolates, susceptibility patterns changed from susceptible to intermediate.

Animals↗
PubMed1988

Necrotizing otitis externa (a new aid to management).

We found the implantation of Gentamicin beads a simple and very inexpensive method for long-term management of malignant (necrotizing) otitis externa. It not only cuts the cost of treatment and shortens the length of stay in hospital but is equally free of potential complications associated with prolonged parenteral Gentamicin therapy.

Aged↗
PubMed1995

Multiple cranial nerve palsy after otitis externa: a case report.

We report in this paper a case of a patient who developed extensive cranial nerve paresis on the left and right side after otitis externa. Investigation revealed an osteomyelitis of the skull base. We describe this disease and stress the importance of the gallium scan in the diagnostic process and therapeutic follow up.

Aged↗
PubMed2005

Isolation and characterization of staphylococci from external auditory meatus of dogs with or without otitis externa with special reference to Staphylococcus schleiferi subsp. coagulans isolates.

Staphylococci were isolated from the external auditory meatus in 14 (48.3%) of 29 dogs affected with otitis externa (OE dogs) and 28 (68.3%) of 41 dogs without OE (non-OE dogs). Twenty-two OE isolates were identified as belonging to 12 species, and 42 non-OE isolates were identified as belonging to 13 species. The predominant species found in both OE and non-OE isolates were S. intermedius, and S. epidermidis. Thirty-eight (59.4%) of 64 isolates were resistant to one or more of the 17 antimicrobial agents tested. Resistance to PCG and ABPC was most frequent. S. schleiferi subsp. coagulans, a recent etiologic agent of canine OE, was isolated from OE and non-OE dogs. All of the 5 S. schleiferi subsp. coagulans isolates showed typical characteristics. No clear difference in the extracellular enzyme or toxin profiles, nor in the PFGE patterns, was demonstrated between the OE and non-OE isolates of S. schleiferi subsp. coagulans. A new PCR primer set specific for 16S rDNA was designed to identify strains of S. schleiferi subsp. coagulans. The amplified fragment was detected in all of the 5 isolates as well as the type strain GA 211 (=JCM 7470) and a reference strain GA 11, but was not detected in any strains of the related species, S. aureus, S. intermedius and S. hyicus. The PCR may allow a simple, rapid and precise identification of S. schleiferi subsp. coagulans, in addition to the standard tube test for free coagulase.

Animals↗
PubMed2001

Improving standards in the treatment of acute otitis externa by the use of a treatment protocol and open access to aural toilet.

A prospective audit of the procedure and outcome in the management of acute otitis externa was undertaken in our unit. The first cycle demonstrated a heterogeneous approach and clinical isolation of junior staff. A questionnaire survey of local general practitioners highlighted clinical confusion over the use of topical medication and a need for improved access to facilities for aural toilet. General practitioner liaison and education was an essential component in formulating a change in practice. In particular, open access for aural toilet was introduced and utilization encouraged. Following changes in practice, the second cycle of the audit showed that treatment protocols were effective and adhered to by junior staff.

Acute Disease↗
PubMed1979

Evaluation of a cuprimyxin-hydrocortisone acetate suspension in the treatment of otitis externa in dogs and cats.

The therapeutic efficacy of a 0.5% cuprimyxin plus 1% hydrocortisone acetate-water-base suspension was evaluated in 130 clinical cases of otitis externa in dogs and cats in various geographic areas of the United States. The otic microbial flora was studied before treatment in 125 (96%) of the dogs and cats, with multiple isolates recovered from mated from 70%, yeasts from 65%, and fungi from 5% of the animals. Evens though multiple drug reistance was frequently observed in the bacterial flora, all bacteria and yeast isolates were sensitive to cuprimyxin. Of the 130 treated animals, a statistically significant (P less than 0.01) favorable response was obtained in 84,6% and no response in 13;1%; in2.3%, the condition became worse. An adverse reaction (pain at the time of first application) was observed in 1 (0.8%) animal.

Acetates↗
PubMed2006

The efficacy of an antiseptic and microbial anti-adhesive ear cleanser in dogs with otitis externa.

A new antimicrobial ear cleanser was evaluated for the treatment of bacterial and yeast ear infection in dogs. Forty-five dogs with erythemato-ceruminous or purulent otitis externa were randomly allocated to two treatment groups: reference ear cleanser (Epiotic, Virbac) or test ear cleanser (Epiotic Advanced, Virbac). Ear cleansing was performed twice daily for 2 weeks, and no other treatment was allowed. By week 2, clinical (exudate quantity, erythema, stenosis, excoriation, and odor) and discomfort (pain, ear scratching, and head shaking) scores were significantly decreased (P < .0001 for all) and no microbial overgrowth could be detected in 25 (64.1%) and 32 (68.1%) ears treated with Epiotic and Epiotic Advanced, respectively. The new pH-balanced, propylene glycol-free test ear cleanser, which incorporates microbial adhesin-blocking carbohydrates, proved as effective as the reference acidic formula.

Administration, Topical↗
PubMed1994

[Local treatment of otitis media and otitis externa: the role of quinolones].

Patients suffering from suppurative otitis media and externa, and in whom pseudomonas species are present, were treated twice daily by local instillation of ciprofloxacin 0.2%. Treatment resulted in clinical and bacteriological cure in all 17 patients, including patients resistant to previous therapy, within a mean time of six days. There were no adverse effects except one case of local allergy. Audiograms remained unchanged. Local therapy with ciprofloxacin is a welcome addition but should be reserved for cases resistant to other therapy.

Audiometry↗
PubMedDate not supplied

Diffuse otitis externa: clinical and microbiologic findings in the course of a multicenter study on a new otic solution.

This report reviews the literature on the epidemiology, pathogenesis and bacteriology of diffuse otitis externa. Four departments of otolaryngology undertook identical studies of these factors, as well as the efficacy and safety of two similar antibiotic-corticosteroid formulations; one a suspension and the other a clear solution. A total of 239 patients, or 283 ears, were studied, utilizing objective clinical as well as correlative bacteriologic criteria. A high degree of clinical and bacteriologic efficacy was demonstrated by the medications irrespective of the formulation, infecting organism, patient's age, length of disease history, severity, or geographic location. There was no statistical difference between either formulation, both achieving a clinical efficacy rate of 97% and a bacteriologic efficacy rate of 83%. Drug related side effects occurred in 1.9% of the patients given the solution and in 1.1% of those given the suspension.

Adolescent↗